Illkirch Graffenstaden, France – May 18, 2017 – Anagenesis Biotechnologies announced today a strategic research agreement with Boehringer Ingelheim, which grants Boehringer Ingelheim an exclusive access to Anagenesis’ proprietary Paraxial Mesoderm Multipotent Cells (P2MCs) technology for chronic muscle diseases. BI-ANAG PR May 18 2017 BI - Anagenesis CP_18 mai 2017
Anagenesis Biotechnologies launches its US subsidiary, Anagenesis Biotherapies Inc. in Boston, Massachusetts to carry out its cell therapy programs. PR AnaG Biotherapies EN CP AnaG Biotherapies FR Anagenesis Biotherapies - MLSC PR 04-19-2016
Anagenesis Biotechnologies and Ksilink announce a collaborative research agreement to develop new small molecule therapies against DMD. PR collab Anagenesis-KSILINK_VF_EN PR collab Anagenesis-KSILINK_VF_FR
Anagenesis Biotechnologies announced today a key publication in Nature Biotechnology. The article is entitled “Differentiating embryonic stem cells to muscle fibers to model Duchenne Muscular Dystrophy” by Jérôme Chal et al. from the lab of Pr Olivier Pourquié (the two scientists inventors of Anagenesis Biotechnologies technology) together with co-authors from Anagenesis Biotechnologies. Lean more in our press release:...
Anagenesis Biotechnologies has been selected to present at Biopharm America 2015. The Event will be held from September 15th to September 17th, 2015. BioPharm America - Bing www.ebdgroup.com/bpa/program